Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Albumin-bound paclitaxel combined with a PD-1 antibody for recurrent, metastatic, or refractory cervical cancer
ChiCTR2000034427Phase 2Not yet recruiting
- Sponsor
- Peking University Cancer Hospital & Institute
- Start
- Jul 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of paclitaxel in Cervical Cancer (CC), sponsored by Peking University Cancer Hospital & Institute. Primary endpoint: objective response rate. Planned start Jul 2020; status: not yet recruiting.
02
Drugs
paclitaxel
03
Conditions
Cervical Cancer (CC)
Beyond the preview
Go deeper on ChiCTR2000034427.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000034427.